سعر اميجراويست amigrawest‏ 2.5 مجم 4 اقراص 2026

Zolmitriptan 2.5 mg film-coated tablets, pack of 4 (Western Pharmaceutical Industries).

• Most common (≥5% and > placebo): neck/throat/jaw pain, tightness or pressure; dizziness; paraesthesia; asthenia; somnolence; warm/cold sensation; nausea; heaviness; dry mouth.International label, same formulation · DailyMed (NLM)

• Ischaemic coronary artery disease or coronary vasospasm; Wolff-Parkinson-White or other accessory conduction pathway arrhythmias; history of stroke, TIA, or hemiplegic or basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; use within 24 hours of another 5-HT1 agonist or ergot; MAO-A inhibitor use within 2 weeks; hypersensitivity.International label, same formulation · DailyMed (NLM)

• Myocardial ischaemia, infarction, arrhythmias, chest/throat/neck/jaw tightness, cerebrovascular events, other vasospasm reactions, medication-overuse headache, serotonin syndrome and blood pressure increases may occur.International label, same formulation · DailyMed (NLM)

• Ergot-containing drugs, other 5-HT1 agonistsAdditive vasospastic effects; do not use within 24 hours of each other.DailyMed (NLM)
• MAO-A inhibitorsIncrease zolmitriptan exposure; contraindicated within 2 weeks of MAO-A inhibitor use.DailyMed (NLM)
• SSRIs, SNRIs, TCAs, MAOIsSerotonin syndrome reported with triptans.DailyMed (NLM)

• No adequate data on developmental risk in pregnant women; in animal studies zolmitriptan caused embryolethality and fetal abnormalities at clinically relevant exposures.International label, same formulation · DailyMed (NLM)
• No data on presence in human milk; in rats milk levels were about 4 times plasma; consider benefits of breastfeeding and the mother's need for the drug.International label, same formulation · DailyMed (NLM)

• Zolmitriptan: Agonist at 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves (US label 12.1).